Britain and America have signed a significant trade agreement that will maintain no import taxes on British drug shipments going into the American market.
The Terms of the Accord
As part of the deal, the UK has committed to raise funding on pharmaceuticals through the NHS. This move guarantees that duties on these crucial exports will be held at nothing for a duration of the next three years.
This agreement follows recent threats to significantly raise duties on branded drug imports, with increases discussed reaching 100%.
"This arrangement with the United Kingdom reinforces the worldwide climate for new treatments and establishes long-overdue balance to American-British drug exports," a statement declared.
Economic Significance
Medicines represent one of the UK's biggest exports to the US, which is by far the largest market for large companies like GSK and AstraZeneca.
Export figures indicate that in the year prior to September, the UK sold medicines valued at £11.1bn to the US. This figure represented nearly one-fifth of British export trade in that span.
"This deal secures employment, stimulates investment and facilitates the UK to emerge as a international leader for biotech and pharma," a government official commented.
Detailed UK Commitments
The pact involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to increase total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount manufacturers must refund to the NHS to stay within budget will be restricted at 15%. Last year, refunds were more than 20%.
Recent Tensions
The deal takes place against a protracted dispute between the sector and the UK government over spending levels and NHS adoption.
The disagreement were intensified by claims that US patients were paying several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been delayed or abandoned, while major funding commitments have been announced toward American operations.
A senior figure publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had shrunk as a share of its overall budget over the last ten years.
